A Validation Study for Recurrence Risk Stratification of Stage II Colon Cancer Using the 55-Gene Classifier

Eiji Shinto, Eiji Oki, Mototsugu Shimokawa, Shigeki Yamaguchi, Megumi Ishiguro, Masaru Morita, Tetsuya Kusumoto, Naohiro Tomita, Yojiro Hashiguchi, Masafumi Tanaka, Shinobu Ohnuma, Sachiyo Tada, Tomoko Matsushima, Kazuo Hase

研究成果: ジャーナルへの寄稿学術誌査読

5 被引用数 (Scopus)


DNA microarrays, such as the consensus molecular subtype (CMS) classification using 600 genes, are used to predict cancer patient prognosis. We recently constructed a simple 55-gene classifier (55GC) system to risk stratify colon cancer (CC). Objective: Here, we validate the 55GC specifically for stage II CC and compare it with CMS categories. Methods: Tissue sections from 232 stage II CC patients who underwent curative surgery without adjuvant chemotherapy between 2009 and 2012 were subjected to DNA microarray analysis. Results: Based on the 55GC, patients were classified into microsatellite instability-like (27%), chromosomal instability-like (41%), and stromal (32%) subtypes with 5-year relapse-free survival (RFS) rates of 88.5, 83.3, and 71.2%, respectively (stromal vs. others: p = 0.0049). Multivariate analysis by Cox's proportional hazard model revealed that the stromal subtype, pT4, and the number of lymph nodes examined (<12) were independent poor prognostic factors. The overall concordance rate between 55GC and CMS was 72%, and 5-year RFS rates of patients with CMS1, CMS2, CMS3, and CMS4 cancers were 100, 85.5, 92.3, and 73.0%, respectively (p = 0.0113). Conclusions: We conclude that the 55GC is a useful and reproducible grading system for stage II CC recurrence risk stratification.

ジャーナルOncology (Switzerland)
出版ステータス出版済み - 8月 1 2020

!!!All Science Journal Classification (ASJC) codes

  • 腫瘍学
  • 癌研究


「A Validation Study for Recurrence Risk Stratification of Stage II Colon Cancer Using the 55-Gene Classifier」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。